Research programme: complement system protein inhibitor therapeutics - Annexon BiosciencesAlternative Names: ANX 007; Classical complement pathway inhibitors - Annexon Biosciences; Neurodegenerative and autoimmune disease antibody therapeutics - Annexon
Latest Information Update: 22 Sep 2016
At a glance
- Originator Annexon
- Class Monoclonal antibodies
- Mechanism of Action Complement C1 inhibitors; Complement system protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Eye disorders; Neurodegenerative disorders